Delegates learn about new NHS Innovation and Technology Tariff

Around 70 delegates from the NHS and industry attended a special event last week to learn more about the new NHS Innovation and Technology Tariff and the benefits this will deliver.

The Leeds information evening was hosted by the NHS Innovation Accelerator, in partnership with local Academic Health Science Network (AHSNs): Yorkshire & Humber, Greater Manchester, the Innovation Agency and North East and North Cumbria AHSN.

Following the launch of the NHS Innovation and Technology Tariff on 1 April 2017, NHS providers and commissioners can now be reimbursed via NHS England for implementing specified cost-saving, outcomes-based innovations. These innovations include:

  • MyCOPD: Online self-management system for COPD proven to reduce acute hospital admissions (saving Clinical Commissioning Groups (CCGs) £370,000 per year), NHS spending and improve the quality of patients’ lives
  • The Non-Injectable Arterial Connecter (NIC): Patient safety device that stops medication being accidentally given through the arterial lines used to monitor the blood of patients in ICUs and operating theatres. Improves safety while offering regional savings of over £156,500 per year
  • PneuX Prevention System: Patient safety device designed to stop ventilator-associated pneumonia (VAP), affecting some 20,000 patients each year, around a third of whom will die, with each episode costing the NHS between £10,000 and £20,000
  • Episcissors-60: Guiding mediolateral episiotomy evidenced to minimise the risk of obstetric anal sphincter injury (OASIS), delivering savings through reduced litigation costs, elective caesarean sections and repair (£1,625 per patient)
  • AliveCor’s Kardia: Mobile ECG device for the identification and measurement of atrial fibrillation (AF) – the cause of between 25,000-35,000 strokes in the UK per year
  • Urolift: Prostatic urethral lift system to treat lower urinary tract symptoms of benign prostatic hyperplasia as a day case. The existing treatment pathway usually involves a hospital stay of three days

The Leeds information evening was opened by Dr Liz Mear, Chair of the AHSN Network and Chief Executive of the Innovation Agency. She outlined how AHSNs make a difference in the NHS, their support for the NHS Innovation Accelerator and explained how:

  • 3 million people have benefitted from AHSN activity
  • 226 innovations have been adopted via significant AHSN involvement
  • Over £330 million innovation funding has been leveraged by AHSNs
  • AHSN-enabled innovations have been implemented in over 11,400 sites

Rob Chesters, Senior Innovation and Research Manager at NHS England went on to explain that the Innovation and Technology Tariff was introduced to incentivise the adoption and spread of transformational innovation in the NHS. It aims to remove the need for multiple local price negotiations and guarantee automatic reimbursement when an approved innovation is used.

At the same time, the ITT allows NHS England to optimise its purchasing power and negotiate national ‘bulk buy’ price discounts where applicable on behalf of the NHS.

He outlined the products available and how the ITT will work in practice, including NHS reporting procedures.

Delegates were then able to listen to presentations from representatives of the innovations already listed on the Innovation and Technology Tariff. These included:

  • Ian Thomson, Strategic Director, my mhealth on myCOPD
  • Dr Dharmesh Kapoor, an NIA Fellow, on Episcissors-60
  • Francis White, an NIA Fellow, on AliveCor’s Kardia
  • Lucy Kirkpatrick, Managing Director of Medtech Strategies Ltd on Urolift
  • Dr Maryanne Mariyaselvam, an NIA Fellow, on the Non-injectable arterial connector (NIC) and PneuX

Slides from the event are available here:

Guidance on implementing the innovations is available below:

  • myCOPD
  • Episcissors-60
  • AliveCor’s Kardia
  • NIC
  • PneuX
  • Urolift (This is covered by the National Tariff. Data about use of the procedure will be collected through National Tariff audit process and specific data reporting requirements are not included in the ITT)